Literature DB >> 9402862

The association of HLA-DRB genes and the shared epitope with rheumatoid arthritis in Pakistan.

K Hameed1, S Bowman, E Kondeatis, R Vaughan, T Gibson.   

Abstract

The association of particular HLA-DR alleles and the shared epitope with rheumatoid arthritis (RA) is now well established. The strength of these links varies between races. Furthermore, the proposition that the presence of the shared epitope is indicative of severe disease has been more difficult to sustain in non-Europeans. This study examines the frequency of HLA-DR and HLA-DRB1 amongst Pakistanis for the first time. Using the polymerase chain reaction (PCR) and sequence-specific oligonucleotide probes (PCR-SSOP) and primers (PCR-SSP), HLA-DR phenotype and genotype frequencies were ascertained in 86 RA hospital out-patients and 79 healthy controls matched for age, gender and ethnicity. HLA-DR1 and HLA-DR4 frequency was similar in patients and controls. HLA-DR10 occurred in 26 instances (15%) in RA and in eight (5%) controls (Pcorr = 0.048). HLA-DR2 was also increased in patients (P = 0.053) and its major subtype DR15 was significantly increased (Pcorr = 0.03). HLA-DR5 frequency was 5% in patients and 19% in controls (Pcorr = 0.002). The HLA-DR4 alleles possessing the shared epitope were more common in RA (Pcorr = 0.03) and this difference was enhanced by inclusion of other alleles possessing the shared epitope (Pcorr = 0.002). Shared epitope alleles were observed in 43 (50%) patients and 17 (22%) controls (Pcorr = 0.003). The shared epitope did not distinguish patients with more severe disease, as reflected by pain, joint deformities, disability, rheumatoid factor or X-ray damage. The distribution of HLA-DR alleles in Pakistanis with RA supports the shared epitope hypothesis. In common with other non-European racial groups, HLA-DR4 was not associated with RA. Unlike other groups, there was a weak link of RA with HLA-DR2. A protective effect of HLA-DR5 was apparent. In accord with some other studies, the shared epitope in this hospital out-patient population was not a marker for more severe disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9402862     DOI: 10.1093/rheumatology/36.11.1184

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  6 in total

1.  HLA-DRB1 frequency in patients with familial and sporadic rheumatoid arthritis in north east of Iran.

Authors:  Massoud Saghafi; Najmeh Nohesara; Houshang Rafatpanah; Jaleh Shariati; Mohamad Taghi Shakeri
Journal:  Clin Rheumatol       Date:  2014-04-24       Impact factor: 2.980

2.  Rheumatoid arthritis and genetic markers in Syrian and French populations: different effect of the shared epitope.

Authors:  Leyla Kazkaz; Hubert Marotte; Mayassa Hamwi; Marie Angélique Cazalis; Pascal Roy; Bruno Mougin; Pierre Miossec
Journal:  Ann Rheum Dis       Date:  2006-10-26       Impact factor: 19.103

3.  Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals progression of erosions despite clinical improvement.

Authors:  F M McQueen; N Stewart; J Crabbe; E Robinson; S Yeoman; P L Tan; L McLean
Journal:  Ann Rheum Dis       Date:  1999-03       Impact factor: 19.103

4.  Greek rheumatoid arthritis patients have elevated levels of antibodies against antigens from Proteus mirabilis.

Authors:  Georgios Christopoulos; V Christopoulou; J G Routsias; A Babionitakis; C Antoniadis; G Vaiopoulos
Journal:  Clin Rheumatol       Date:  2016-10-08       Impact factor: 2.980

5.  Evaluation of differences in HLA-DR4 gene and its subtypes prevalence among healthy people and RA patients in Isfahan province population.

Authors:  Mansour Salesi; Golshan Taghipour Boroujeni; Mansoor Salehi; Somaieh Farzamnia
Journal:  Adv Biomed Res       Date:  2016-01-29

6.  Association of HLA-DRB1 and -DQB1alleles and haplotypes with rheumatoid arthritis in a Pakistani population.

Authors:  Ambreen Gul Muazzam; Atika Mansoor; Lubna Ali; Saima Siddiqi; Abdul Hameed; Muhammad Ajmal; Kehkashan Mazhar
Journal:  Arthritis Res Ther       Date:  2013-08-22       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.